Drug resistance in visceral leishmaniasis

Journal of Biomedicine and Biotechnology

Volumn 2010, Issue , 2010, Pages

  Maltezou, Helena C ^a  

^a Hellenic Center for Disease Control and Prevention   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTILEISHMANIAL AGENT; ANTIMONY; ANTIMONY GLUCONATE; DIPEROXOVANADATE; MEGLUMINE ANTIMONATE; MILTEFOSINE; PAROMOMYCIN; STIBOGLUCONATE SODIUM; UNCLASSIFIED DRUG; VERAPAMIL; ANTIPROTOZOAL AGENT;

ANTIPROTOZOAL ACTIVITY; CHILL; COMBINATION CHEMOTHERAPY; DISEASE TRANSMISSION; DRUG POTENTIATION; DRUG WITHDRAWAL; FEVER; GASTROINTESTINAL TOXICITY; HEART ARRHYTHMIA; HUMAN; HYPERTRANSAMINASEMIA; HYPOKALEMIA; IMMUNE RESPONSE; IMMUNOMODULATION; INJECTION SITE PAIN; MONOTHERAPY; NEPHROTOXICITY; NONHUMAN; OTOTOXICITY; PANCREATITIS; PATHOGENESIS; PNEUMONIA; REVIEW; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; VISCERAL LEISHMANIASIS; DRUG COMBINATION; DRUG EFFECT; DRUG RESISTANCE; IMMUNOLOGY; PARASITOLOGY;

ANTIPROTOZOAL AGENTS; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; HUMANS; LEISHMANIASIS, VISCERAL;

EID: 74049122035     PISSN: 11107243     EISSN: 11107251     Source Type: Journal    
DOI: 10.1155/2010/617521     Document Type: Review

References (65)

1. World Health Organization, "Leishmaniasis: burden of disease," August 2009, http://www.who.int/leishmaniasis/burden/en.
2. H. C. Maltezou, C. Siafas, M. Mavrikou, et al., "Visceral leishmaniasis during childhood in Southern Greece," Clinical Infectious Diseases, vol. 31, no. 5, pp. 1139-1143, 2000. (Pubitemid 32295440)
3. P. Minodier, R. Piarroux, J.-M. Garnier, D. Unal, H. Perrimond, and H. Dumon, "Pediatric visceral leishmaniasis in Southern France," Pediatric Infectious Disease Journal, vol. 17, no. 8, pp. 701-704, 1998. (Pubitemid 28388159)
4. M.-E. Raguenaud, A. Jansson, V. Vanlerberghe, et al., "Epidemiology and clinical features of patients with visceral leishmaniasis treated by an MSF clinic in Bakool Region, Somalia, 2004-2006," PLoS Neglected Tropical Diseases, vol. 1, no. 1, article e85, 2007.
5. World Health Organization, "Global plan to combat neglected tropical diseases 2008-2015," August 2009, http://whqlibdoc.who.int/hq/2007/ WHOCDSNTD2007.3 eng.pdf.
6. S. Sundar, J. Chakravarty, V. K. Rai, et al., "Amphotericin B treatment for Indian visceral leishmaniasis: response to 15 daily versus alternate-day infusions," Clinical Infectious Diseases, vol. 45, no. 5, pp. 556-561, 2007. (Pubitemid 47328634)
7. J. Alvar, P. Aparicio, A. Aseffa, et al., "The relationship between leishmaniasis and AIDS: the second 10 years," Clinical Microbiology Reviews, vol. 21, no. 2, pp. 334-359, 2008. (Pubitemid 351555511)
8. S. Saha, S. Mondal, A. Banerjee, J. Ghose, S. Bhowmick, and N. Ali, "Immune responses in kala-azar," Indian Journal of Medical Research, vol. 123, no. 3, pp. 245-266, 2006. (Pubitemid 43905567)
9. R. C. Jochim and C. Teixeira, "Leishmania commandeers the host inflammatory response through neutrophils," Trendsin Parasitology, vol. 25, no. 4, pp. 145-147, 2009.
10. E. McFarlane, C. Perez, M. Charmoy, et al., "Neutrophils contribute to development of a protective immune response during onset of infection with Leishmania donovani," Infection and Immunity, vol. 76, no. 2, pp. 532-541, 2008. (Pubitemid 351251723)
11. L. Lachaud, N. Bourgeois, M. Plourde, P. Leprohon, P. Bastien, and M. Ouellette, "Parasite susceptibility to amphotericin B in failures of treatment for visceral leishmaniasis in patients coinfected with HIV type 1 and Leishmania infantum," Clinical Infectious Diseases, vol. 48, no. 2, pp. e16-e22, 2009.
12. N. Marques, R. Sá, F. Coelho, J. Oliveira, J. Saraiva Da Cunha, and A. Melico-Silvestre, "Miltefosine for visceral leishmaniasis relapse treatment and secondary prophylaxis in HIV-infected patients," Scandinavian Journal of Infectious Diseases, vol. 40, no. 6-7, pp. 523-526, 2008. (Pubitemid 351997671)
13. S. Nylen and D. Sacks, "Interleukin-10 and the pathogenesis of human visceral leishmaniasis," Trends in Immunology, vol. 28, no. 9, pp. 378-384, 2007. (Pubitemid 47385375)
14. H. W. Murray, C. M. Lu, S. Mauze, et al., "Interleukin-10 (IL-10) in experimental visceral leishmaniasis and IL-10 receptor blockade as immunotherapy," Infection and Immunity, vol. 70, no. 11, pp. 6284-6293, 2002. (Pubitemid 35192720)
15. N. Rolao, S. Cortes, S. Gomes-Pereira, and L. Campino, "Leishmania infantum: mixed T-helper-1/T-helper-2 immune response in experimentally infected BALB/c mice," Experimental Parasitology, vol. 115, no. 3, pp. 270-276, 2007. (Pubitemid 44828068)
16. J. Alexander, K. Christine-Carter, N. Al-Fasi, A. Satoskar, and F. Brombacher, "Endogenous IL-4 is necessary for effective drug therapy against visceral leishmaniasis," European Journal of Immunology, vol. 30, no. 10, pp. 2935-2943, 2000.
17. R. Basu, S. Bhaumik, A. K. Haldar, et al., "Hybrid cell vaccination resolves Leishmania donovani infection by eliciting a strong CD8+ cytotoxic T-lymphocyte response with concomitant suppression of interleukin-10 (IL-10) but not IL-4 or IL-13," Infection and Immunity, vol. 75, no. 12, pp. 5956-5966, 2007. (Pubitemid 350207836)
18. H. Kothari, P. Kumar, S. Sundar, and N. Singh, "Possibility of membrane modification as a mechanism of antimony resistance in Leishmania donovani," Parasitology International, vol. 56, no. 1, pp. 77-80, 2007. (Pubitemid 46274490)
19. K. C. Carter, S. Hutchison, F. L. Henriquez, et al., "Resistance of Leishmania donovani to sodium stibogluconate is related to the expression of host and parasite γ-glutamylcysteine synthetase," Antimicrobial Agents and Chemotherapy, vol. 50, no. 1, pp. 88-95, 2006. (Pubitemid 43042907)
20. N. Singh, "Drug resistance mechanisms in clinical isolates of Leishmania donovani," Indian Journal of Medical Research, vol. 123, no. 3, pp. 411-422, 2006. (Pubitemid 43905579)
21. III," International Journal for Parasitology, vol. 38, no. 12, pp. 1411-1423, 2008.
22. S. Wyllie, T. J. Vickers, and A. H. Fairlamb, "Roles of trypan-othione S-transferase and tryparedoxin peroxidase in resistance to antimonials," Antimicrobial Agents and Chemotherapy, vol. 52, no. 4, pp. 1359-1365, 2008. (Pubitemid 351521999)
23. S. Sundar, D. K. More, M. K. Singh, et al., "Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic," Clinical Infectious Diseases, vol. 31, no. 4, pp. 1104-1107, 2000. (Pubitemid 32299375)
24. R. Singh, D. Kumar, V. Ramesh, N. S. Negi, S. Singh, and P. Salotra, "Visceral leishmaniasis, or Kala Azar (KA): high incidence of refractoriness to antimony is contributed by anthroponotic transmission via post-KA dermal leishmania-sis," Journal of Infectious Diseases, vol. 194, no. 3, pp. 302-306, 2006. (Pubitemid 44116971)
25. S. Sundar, B. B. Thakur, A. K. Tandon, et al., "Clinicoepidemi- ological study of drug resistance in Indian kala-azar," British Medical Journal, vol. 308, no. 6924, p. 307, 1994. (Pubitemid 24084143)
26. M. G. Abdo, W. M. Elamin, E. A. G. Khalil, and M. M. Mukhtar, "Antimony-resistant Leishmania donovani in eastern Sudan: incidence and in vitro correlation," Eastern Mediterranean Health Journal, vol. 9, no. 4, pp. 837-843, 2003. (Pubitemid 40485321)
27. L. Gradoni, K. Soteriadou, H. Louzir, et al., "Drug regimens for visceral leishmaniasis in Mediterranean countries," Tr o p-ical Medicine and International Health, vol. 13, no. 10, pp. 1272-1276, 2008.
28. S. Decuypere, S. Rijal, V. Yardley, et al., "Gene expression analysis of the mechanism of natural Sb(V) resistance in Leish-mania donovani isolates from Nepal," Antimicrobial Agents and Chemotherapy, vol. 49, no. 11, pp. 4616-4621, 2005. (Pubitemid 41552591)
29. A. H. Sharief, E. A. Gasim-Khalil, T. G. Theander, A. Kharazmi, S. A. Omer, and M. E. Ibrahim, "Leishmania dono-vani: an in vitro study of antimony-resistant amphotericin B-sensitive isolates," Experimental Parasitology, vol. 114, no. 4, pp. 247-252, 2006. (Pubitemid 44634428)
30. III," International Journal for Parasitology, vol. 38, no. 12, pp. 1411-1423, 2008.
31. A. Mukherjee, P. K. Padmanabhan, S. Singh, et al., "Role of ABC transporter MRPA, γ-glutamylcysteine synthetase and ornithine decarboxylase in natural antimony-resistant isolates of Leishmania donovani," Journal of Antimicrobial Chemotherapy, vol. 59, no. 2, pp. 204-211, 2007. (Pubitemid 47072058)
32. F. Cortés-Selva, I. A. Jiménez, F. Muñoz- Martínez, et al., "Dihidro-β-agarofuran sesquiterpenes: a new class of reversal agents of the multidrug resistance phenotype mediated by P-glycoprotein in the protozoan parasite Leishmania," Current Pharmaceutical Design, vol. 11, no. 24, pp. 3125-3159, 2005. (Pubitemid 41149929)
33. M. K. Mittal, S. Rai, A. Ravinger, S. Gupta, S. Sundar, and N. Goyal, "Characterization of natural antimony resistance in Leishmania donovani isolates," American Journal of Tropical Medicine and Hygiene, vol. 76, no. 4, pp. 681-688, 2007. (Pubitemid 351627707)
34. G. Mandal, A. Sarkar, P. Saha, N. Singh, S. Sundar, and M. Chatterjee, "Functionality of drug efflux pumps in antimonial resistant Leishmania donovani field isolates," Indian Journal of Biochemistry and Biophysics, vol. 46, no. 1, pp. 86-92, 2009.
35. J. M. Basu, A. Mookerjee, R. Banerjee, et al., "Inhibition of ABC transporters abolishes antimony resistance in Leishmania infection," Antimicrobial Agents and Chemotherapy, vol. 52, no. 3, pp. 1080-1093, 2008. (Pubitemid 351358392)
36. I. L. Wong, K.-F. Chan, B. A. Burkett, et al., "Flavonoid dimers as bivalent modulators for pentamidine and sodium stiboglucanate resistance in Leishmania," Antimicrobial Agents and Chemotherapy, vol. 51, no. 3, pp. 930-940, 2007. (Pubitemid 46355277)
37. T. Laurent, S. Rijal, V. Yardley, et al., "Epidemiological dynamics of antimonial resistance in Leishmania donovani: genotyping reveals a polyclonal population structure among naturally-resistant clinical isolates from Nepal," Infection, Genetics and Evolution, vol. 7, no. 2, pp. 206-212, 2007. (Pubitemid 46172947)
38. A. Kumar, V. R. Boggula, S. Sundar, A. K. Shasany, and A. Dube, "Identification of genetic markers in sodium antimony gluconate (SAG) sensitive and resistant Indian clinical isolates of Leishmania donovani through amplified fragment length polymorphism (AFLP)," Acta Tropica, vol. 110, no. 1, pp. 80-85, 2009.
39. C. P. Thakur, A. K. Pandey, G. P. Sinha, S. Roy, K. Behbehani, and P. Olliaro, "Comparison of three treatment regimens with liposomal amphotericin B (AmBisome) for visceral leishmaniasis in India: a randomized dose-finding study," Transactions of the Royal Society of Tropical Medicine and Hygiene, vol. 90, no. 3, pp. 319-322, 1996. (Pubitemid 26188890)
40. S. Sundar, T. K. Jha, C. P. Thakur, M. Mishra, V. R. Singh, and R. Buffels, "Low-dose liposomal amphotericin B in refractory Indian visceral leishmaniasis: a multicenter study," American Journal of Tropical Medicine and Hygiene, vol. 66, no. 2, pp. 143-146, 2002. (Pubitemid 34755644)
41. K. D. Manandhar, T. P. Yadav, V. K. Prajapati, et al., "Antileish-manial activity of nano-amphotericin B deoxycholate," Journal of Antimicrobial Chemotherapy, vol. 62, no. 2, pp. 376-380, 2008.
42. L. Ordóñez-Gutiérrez, R. Espada-Fernández, M. A. Dea-Ayuela, J. J. Torrado, F. Bolás-Fernandez, and J. M. Alunda, "In vitro effect of new formulations of amphotericin B on amastigote and promastigote forms of Leishmania infantum," International Journal of Antimicrobial Agents, vol. 30, no. 4, pp. 325-329, 2007. (Pubitemid 47361711)
43. J. J. Torrado, R. Espada, M. P. Ballesteros, and S. Torrado-Santiago, "Amphotericin B formulations and drug targeting," Journal of Pharmaceutical Sciences, vol. 97, no. 7, pp. 2405-2425, 2008.
44. S. Gupta, A. Dube, and S. P. Vyas, "Antileishmanial efficacy of amphotericin B bearing emulsomes against experimental visceral leishmaniasis," Journal of Drug Targeting, vol. 15, no. 6, pp. 437-444, 2007. (Pubitemid 47073059)
45. A. Dube, N. Singh, S. Sundar, and N. Singh, "Refractoriness to the treatment of sodium stibogluconate in Indian kala-azar field isolates persist in in vitro and in vivo experimental models," Parasitology Research, vol. 96, no. 4, pp. 216-223, 2005. (Pubitemid 40933669)
46. K. Ritmeijer, A. Dejenie, Y. Assefa, et al., "A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection," Clinical Infectious Diseases, vol. 43, no. 3, pp. 357-364, 2006. (Pubitemid 44078909)
47. S. K. Bhattacharya, P. K. Sinha, S. Sundar, et al., "Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis," Journal of Infectious Diseases, vol. 196, no. 4, pp. 591-598, 2007. (Pubitemid 47206107)
48. F. J. Pérez-Victoria, M. P. Sanchez-Canete, K. Seifert, et al., "Mechanisms of experimental resistance of Leishmania to miltefosine: implications for clinical use," Drug Resistance Updates, vol. 9, no. 1-2, pp. 26-39, 2006. (Pubitemid 43928805)
49. P. Wadhone, M. Maiti, R. Agarwal, V. Kamat, S. Martin, and B. Saha, "Miltefosine promotes IFN-gamma-dominated anti-leishmanial immune response," Journal of Immunology, vol. 182, no. 11, pp. 7146-7154, 2009.
50. K. Seifert, F. J. Pérez-Victoria, M. Stettler, et al., "Inactivation of the miltefosine transporter, LdMT, causes miltefosine resistance that is conferred to the amastigote stage of Leish-mania donovani and persists in vivo," International Journal of Antimicrobial Agents, vol. 30, no. 3, pp. 229-235, 2007. (Pubitemid 47135625)
51. K. Seifert, S. Matu, F. J. Pérez-Victoria, S. Castanys, F. Gamarro, and S. L. Croft, "Characterisation of Leishmania donovani promastigotes resistant to hexadecylphosphocholine (miltefosine)," International Journal of Antimicrobial Agents, vol. 22, no. 4, pp. 380-387, 2003. (Pubitemid 37163727)
52. E. Castanys-Munoz, J. M. Pérez-Victoria, F. Gamarro, and S. Castanys, "Characterization of an ABCG-like transporter from the protozoan parasite Leishmania with a role in drug resistance and transbilayer lipid movement," Antimicrobial Agents and Chemotherapy, vol. 52, no. 10, pp. 3573-3579, 2008.
53. J. M. Pérez-Victoria, F. Cortes-Selva, A. Parodi-Talice, et al., "Combination of suboptimal doses of inhibitors targeting different domains of LtrMDR1 efficiently overcomes resistance of Leishmania spp. to miltefosine by inhibiting drug efflux," Antimicrobial Agents and Chemotherapy, vol. 50, no. 9, pp. 3102-3110, 2006. (Pubitemid 44396418)
54. M. Rakotomanga, M. Saint-Pierre-Chazalet, and P. M. Loiseau, "Alteration of fatty acid and sterol metabolism in miltefosine-resistant Leishmania donovani promastigotes and consequences for drug-membrane interactions," Antimicrobial Agents and Chemotherapy, vol. 49, no. 7, pp. 2677-2686, 2005. (Pubitemid 40917578)
55. B. D. Pandey, K. Pandey, O. Kaneko, T. Yanagi, and K. Hirayama, "Relapse of visceral leishmaniasis after miltefosine treatment in a Nepalese patient," American Journal of Tropical Medicine and Hygiene, vol. 80, no. 4, pp. 580-582, 2009.
56. S. Sundar, T. K. Jha, C. P. Thakur, P. K. Sinha, and S. K. Bhat-tacharya, "Injectable paromomycin for visceral leishmaniasis in India," New England Journal of Medicine, vol. 356, no. 25, pp. 2571-2581, 2007. (Pubitemid 46961002)
57. A. Jhingran, B. Chawla, S. Saxena, M. P. Barrett, and R. Mad-hubala, "Paromomycin: uptake and resistance in Leishmania donovani," Molecular and Biochemical Parasitology, vol. 164, no. 2, pp. 111-117, 2009.
58. Y. Melaku, S. M. Collin, F. Gatluak, K. Ritmeijer, and R. N. Davidson, "Treatment of kala-azar in Southern Sudan using a 17-day regimen of sodium stibogluconate combined with paromomycin: a retrospective comparison with 30-day sodium stibogluconate monotherapy," American Journal of Tropical Medicine and Hygiene, vol. 77, no. 1, pp. 89-94, 2007. (Pubitemid 351844356)
59. K. Seifert and S. L. Croft, "In vitro and in vivo interactions between miltefosine and other antileishmanial drugs," Antimicrobial Agents and Chemotherapy, vol. 50, no. 1, pp. 73-79, 2006. (Pubitemid 43042905)
60. S. Sundar, M. Rai, J. Chakravarty, et al., "New treatment approach in Indian visceral leishmaniasis: single-dose liposo-mal amphotericin B followed by short-course oral miltefos-ine," Clinical Infectious Diseases, vol. 47, no. 8, pp. 1000-1006, 2008.
61. H. C. Maltezou, "Visceral leishmaniasis: advances in treatment," Recent Patents on Anti-Infective Drug Discovery, vol. 3, no. 3, pp. 192-198, 2008.
62. S. Gupta, S. C. Ramesh, and V. M. Srivastava, "Efficacy of picroliv in combination with miltefosine, an orally effective antileishmanial drug against experimental visceral leishmani-asis," Acta Tropica, vol. 94, no. 1, pp. 41-47, 2005. (Pubitemid 40445378)
63. R. Valiathan, M. L. Dubey, R. C. Mahajan, and N. Malla, "Leishmania donovani: effect of verapamil on in vitro susceptibility of promastigote and amastigote stages of Indian clinical isolates to sodium stibogluconate," Experimental Parasitology, vol. 114, no. 2, pp. 103-108, 2006. (Pubitemid 44374508)
64. A. K. Haldar, S. Banerjee, K. Naskar, D. Kalita, N. S. Islam, and S. Roy, "Sub-optimal dose of sodium antimony gluconate (SAG)-diperoxovanadate combination clears organ parasites from BALB/c mice infected with antimony resistant Leishmania donovani by expanding antileishmanial T-cell repertoire and increasing IFN-γ to IL-10 ratio," Experimental Parasitology, vol. 122, no. 2, pp. 145-154, 2009.
65. C. P. Thakur, S. Thakur, S. Narayan, and A. Sinha, "Comparison of treament regimens of kala-azar based on culture and sensitivity amastigotes to sodium antimony gluconate," Indian Journal of Medical Research, vol. 127, no. 6, pp. 582-588, 2008.